Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05304351 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
A Phase 2 study of Herpes Zoster and Shingles, sponsored by Curevo.
- Active
- Registry status
- Phase 2
- Development phase
- 1,516
- Enrollment target
- 14
- Study locations
NCT05304351: Active Phase 2 study of Herpes Zoster and Shingles, sponsored by Curevo.
NCT05304351 is a Phase 2 study of Herpes Zoster and Shingles that is active but no longer recruiting, run by Curevo. The registered enrollment target is 1,516 participants, below the 2,079-participant average among 16 other Herpes Zoster trials with a reported enrollment target (27% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05304351, a Phase 2 study of Herpes Zoster and Shingles, is active but no longer recruiting, sponsored by Curevo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,516 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to assess the safety and immunogenicity of amezosvatein (CRV-101), an investigational vaccine compared to Shingrix® for the prevention of herpes zoster in adults aged 50 years and older
Primary Outcome
Occurrence, severity, and duration of solicited local injection site reactions within 7 days (Day 0-Day 6) following each vaccination. (i.e., pain, redness, swelling) Occurrence, severity, and duration of solicited systemic reactions within 7 days (Day 0-Day 6) following each vaccination. (i.e., myalgia, fatigue, headache, chills, fever)
Conditions Studied
Interventions
- BIOLOGICAL Shingrix
- BIOLOGICAL Amezosvatein Antigen High Dose Arm A
- BIOLOGICAL Amezosvatein Antigen Low Dose Arm B
- BIOLOGICAL Amezosvatein Adjuvant Dose Arm D
- BIOLOGICAL Amezosvatein Adjuvant Dose Arm F
Study Locations (14)
Texas
- Curevo Investigational Site - Austin
- Curevo Investigational Site - Dallas
- Curevo Investigational Site - Euless
Florida
- Curevo Investigational Site - Coral Gables
- Curevo Investigational Site - Tampa
Kansas
- Curevo Investigational Site - Lenexa
- Curevo Investigational Site - Newton
Arizona
- Curevo Investigational Site - Tempe
Illinois
- Curevo Investigational Site - Oak Brook
Kentucky
- Curevo Investigational Site - Lexington
Nevada
- Curevo Investigational Site - Las Vegas
Oklahoma
- Curevo Investigational Site - Edmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,516 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2032-03-06 |
| Phase | Phase 2 |
What the registry record for NCT05304351 still lists
NCT05304351 is an interventional study that assigns participants to a tested intervention. Its 1,516 participants enrollment target places it among the larger protocols in the corpus, below the 2,079-participant average among 16 other Herpes Zoster trials with a reported enrollment target (27% lower).
The record links to 2 conditions, with Herpes Zoster appearing as the primary indexed condition, and to 5 interventions - of which Shingrix is the first listed.
NCT05304351 lists 14 locations in 10 states (Texas, Florida, Kansas).
Frequently Asked Questions
What is clinical trial NCT05304351 about?
NCT05304351 is a clinical study titled "Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older". The purpose of this study is to assess the safety and immunogenicity of amezosvatein (CRV-101), an investigational vaccine compared to Shingrix® for the prevention of herpes zoster in adults aged 50 years and older
What is the current status of trial NCT05304351?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,516 participants. The study started on 2022-02-02. Estimated completion is 2032-03-06.
What conditions does trial NCT05304351 study?
This clinical trial studies the following conditions: Herpes Zoster, Shingles.
What interventions are being tested in trial NCT05304351?
The interventions under investigation include: Shingrix (BIOLOGICAL), Amezosvatein Antigen High Dose Arm A (BIOLOGICAL), Amezosvatein Antigen Low Dose Arm B (BIOLOGICAL), Amezosvatein Adjuvant Dose Arm D (BIOLOGICAL), Amezosvatein Adjuvant Dose Arm F (BIOLOGICAL).
Who is sponsoring clinical trial NCT05304351?
This trial is sponsored by Curevo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05304351 being conducted?
This trial has 14 study locations across Arizona, Florida, Illinois, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05304351's enrollment target sits among peer trials
1,516 5th of 16 higher than 12 of 16 other Herpes Zoster trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Herpes Zoster trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
ACTIVE NOT RECRUITING · Phase 2
-
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
COMPLETED · Phase 2
-
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years
COMPLETED · Phase 2
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
-
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT07232017 · 1,520 participants
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI